Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
97 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Low Back Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Low Back Pain - Pipeline Review, H2 2014', provides an overview of the Low Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Low Back Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Low Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Low Back Pain Overview 8 Therapeutics Development 9 Pipeline Products for Low Back Pain - Overview 9 Pipeline Products for Low Back Pain - Comparative Analysis 10 Low Back Pain - Therapeutics under Development by Companies 11 Low Back Pain - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Low Back Pain - Products under Development by Companies 16 Low Back Pain - Companies Involved in Therapeutics Development 17 Aestus Therapeutics, Inc. 17 Astellas Pharma Inc. 18 Collegium Pharmaceutical, Inc. 19 Eisai Co., Ltd. 20 Eli Lilly and Company 21 Endo Pharmaceuticals Inc. 22 GlobalAcorn 23 Grunenthal GmbH 24 Ipsen S.A. 25 MEDRx Co., Ltd. 26 Merck & Co., Inc. 27 Mesoblast Limited 28 Paladin Labs Inc. 29 Pfizer Inc. 30 Purdue Pharma L.P. 31 Teikoku Pharma USA, Inc. 32 Teva Pharmaceutical Industries Limited 33 Low Back Pain - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Combination Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 (acetaminophen + tramadol hydrochloride) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 (diclofenac sodium + eperisone) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (etodolac + lidocaine) - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (etoricoxib + tizanidine) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 (oxycodone hydrochloride + naltrexone) ER - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 abobotulinumtoxin A - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ASP-7962 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Atx09-002 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 buprenorphine hydrochloride - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 cebranopadol - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 duloxetine hydrochloride DR - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 eperisone - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 flurbiprofen - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 GA-8SMOL-PAIN - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 hydrocodone bitartrate ER - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 hydrocodone bitartrate ER - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MPC-06-ID - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 oxycodone hydrochloride ER - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 PF-06372865 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Low Back Pain - Recent Pipeline Updates 71 Low Back Pain - Dormant Projects 84 Low Back Pain - Discontinued Products 85 Low Back Pain - Product Development Milestones 86 Featured News & Press Releases 86 Apr 30, 2014: Purdue Pharma Submits NDA For Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated To Incorporate Abuse-Deterrent Properties 86 Apr 30, 2014: Teva Pharmaceutical Reports Positive Results From Pivotal Phase 3 Study To Evaluate Hydrocodone Bitartrate Extended-Release Tablets For Moderate To Severe Chronic Low Back Pain 88 Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin 89 Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform 90 Mar 12, 2014: Purdue Pharma L.P. Announces Positive Phase 3 Clinical Trial Results of Once-Daily Hydrocodone Bitartrate Extended-Release Tablets 90 Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 91 Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 92 Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 93 Apr 22, 2013: Mesoblast Reports Positive Interim Results In Phase II Trial Of Adult Stem Cells For Intervertebral Disc Repair 93 Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 94 Appendix 96 Methodology 96 Coverage 96 Secondary Research 96 Primary Research 96 Expert Panel Validation 96 Contact Us 97 Disclaimer 97
List of Tables Number of Products under Development for Low Back Pain, H2 2014 9 Number of Products under Development for Low Back Pain - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H2 2014 17 Low Back Pain - Pipeline by Astellas Pharma Inc., H2 2014 18 Low Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 19 Low Back Pain - Pipeline by Eisai Co., Ltd., H2 2014 20 Low Back Pain - Pipeline by Eli Lilly and Company, H2 2014 21 Low Back Pain - Pipeline by Endo Pharmaceuticals Inc., H2 2014 22 Low Back Pain - Pipeline by GlobalAcorn, H2 2014 23 Low Back Pain - Pipeline by Grunenthal GmbH, H2 2014 24 Low Back Pain - Pipeline by Ipsen S.A., H2 2014 25 Low Back Pain - Pipeline by MEDRx Co., Ltd., H2 2014 26 Low Back Pain - Pipeline by Merck & Co., Inc., H2 2014 27 Low Back Pain - Pipeline by Mesoblast Limited, H2 2014 28 Low Back Pain - Pipeline by Paladin Labs Inc., H2 2014 29 Low Back Pain - Pipeline by Pfizer Inc., H2 2014 30 Low Back Pain - Pipeline by Purdue Pharma L.P., H2 2014 31 Low Back Pain - Pipeline by Teikoku Pharma USA, Inc., H2 2014 32 Low Back Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 33 Assessment by Monotherapy Products, H2 2014 34 Assessment by Combination Products, H2 2014 35 Number of Products by Stage and Target, H2 2014 37 Number of Products by Stage and Mechanism of Action, H2 2014 39 Number of Products by Stage and Route of Administration, H2 2014 41 Number of Products by Stage and Molecule Type, H2 2014 43 Low Back Pain Therapeutics - Recent Pipeline Updates, H2 2014 71 Low Back Pain - Dormant Projects, H2 2014 84 Low Back Pain - Discontinued Products, H2 2014 85
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.